Publications
Probity Medical Research has compiled journals, articles and presentations for your personal review. Please use the search features below to find an article.
If you would like to request an article for personal review please complete the registration form. These publications are for personal use only and cannot be distributed.
Already granted access to an article?
If you cannot find the article you are looking for please contact Probity Medical Research.
Journals, Articles and Presentations
Articles by Publication Year
CNTO 1275 (anti-IL-12/23p40) Treatment of Psoriasis: Phase 3 Trial Results
Presented at the AAD 66th Annual Meeting, San Antonio, Texas February 2008 and 32nd Hawaii Dermatology Seminar, Waikoloa, Hawaii, March 2008
A Phase 2 Study Demonstrating the Efficacy and Safety of the Oral Therapy CC-10004 in Subjects with Moderate to Severe Psoriasis
Presented at the AAD 66th Annual Meeting, San Antonio, Texas, USA, February 2008
Efficacy of ISA247 in plaque psoriasis a randomised, multicentre, double-blind, placebo-controlled phase III study
Lancet. 2008 Apr 19;371(9621):1337-42.
Psoriasis: consensus on topical therapies
Journal of the European Academy of Dermatology and Venereology 2008 Jul;22(7):859-70. Epub 2007 Dec 13.
Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis
British Journal of Dermatology 2008 Mar;158(3):549-57. Epub 2007 Nov 28.
Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)
British Journal of Dermatology 2008 Mar;158(3):558-66. Epub 2007 Nov 28.
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Lancet 2008 May 17;371(9625):1665-74.
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
Lancet 2008 May 17;371(9625):1675-84.
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
Journal of American Acadamy of Dermatology 2008 Jan;58(1):106-15. Epub 2007 Oct 23.
A study examining inter-rater and intrarater reliability of a novel instrument for assessment of psoriasis: the Copenhagen Psoriasis Severity Index
British Journal of Dermatology 2008 Aug;159(2):407-12. Epub 2008 Jun 28.
About PMR | Investigators | Experience | Locations | News | Publications | Privacy Policy | Contact | Sitemap |
Copyright 2014 Probity Medical Research Inc. All Rights Reserved.